Edwards Lifesciences Corporation

Stage 3 · Topping · week 5

As of Oct 22, 2026, Edwards Lifesciences is in Stage 3, the topping phase, now in week 5 (since Sep 21, 2026). It closed at $90.09, 5.3% below its 52-week high and above its 200-day average, which is rising.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. More about the company

$90.09

+1.91% today

$51.9B · Large cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is EW early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S1 14w

S2 21w

S2 20w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 4w → S4 14w → S1 8w → S2 13w → S3 7w → S2 3w → S3 2w → S4 10w → S1 3w → S4 2w → S1 14w → S4 5w → S3 4w → S2 21w → S3 5w → S2 12w → S3 13w → S2 20w → S3 5w current

Total tracked: 165 weeks across 19 stage runs.

EW among Medical Devices32nd of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…32	EWEdwards Lifesciences Corporation	Stage 3 · wk 5	69	+3.8%

vs 52W High

-5.3%

$75.87 lo$95.18 hi

5.3% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 5

1w13w26w

Week 5, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

5.7%

200 DMA: $85.21 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.94x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

→

Short-term trend flat

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+3.8%

+9.0%

+13.0%

YTD

+5.6%

+18.5%

Scan Membership

Breakout Watch

Latest: 2025-05-13

10 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 5 · Vol 0.94x

2026-10-21S3

Wk 5 · Vol 0.67x

2026-10-20S3

Wk 5 · Vol 0.54x

2026-10-19S3

Wk 5 · Vol 0.83x

2026-10-16S3

Wk 4 · Vol 1.22x

2026-10-15S3

Wk 4 · Vol 1.43x

2026-10-14S3

Wk 4 · Vol 1.23x

2026-10-13S3

Wk 4 · Vol 1.11x

2026-10-12S3

Wk 4 · Vol 1.01x

2026-10-09S3

Wk 3 · Vol 1.18x

2026-10-08S3

Wk 3 · Vol 1.99x

2026-10-07S3

Wk 3 · Vol 1.05x

Moving averages & range

50 DMA

$88.13

200 DMA

$85.21

52W High

$95.18

52W Low

$75.87

5D Low

$86.60

Resistance levels (recent highs)

20d High

$90.09

60d High

$93.66

120d High

$95.18

250d High

$95.18

Next resistance

+4.0%

to 60d High

P/E (TTM)

53.6

Forward 26.6

Earnings Growth (YoY)

-25.4%

Revenue +13.6%

ROE

+9.2%

Profit margin +15.4%

Dividend Yield

0.00%

P/B 4.9

Edwards Lifesciences: quick answers

What stage is Edwards Lifesciences in?

As of Oct 22, 2026, Edwards Lifesciences (EW) is in Stage 3, the topping phase. It entered Stage 3 on Sep 21, 2026 and is in week 5. What the four stages mean

Is Edwards Lifesciences in an uptrend?

Its uptrend has stalled. Edwards Lifesciences is in Stage 3, the topping phase that follows an advance. It trades 5.7% above its 200-day average, which is rising.

How far is Edwards Lifesciences from its 52-week high?

Edwards Lifesciences closed at $90.09 on Oct 22, 2026, 5.3% below its 52-week high of $95.18. Its 52-week low is $75.87.

How has Edwards Lifesciences performed over the past year?

As of Oct 22, 2026, Edwards Lifesciences is up 18.5% over the past year and up 5.6% so far in 2026.

Which sector and industry is Edwards Lifesciences in?

Edwards Lifesciences is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.